

HBV Forum 13 Meeting

Thursday, November 14, 2024

Alma San Diego, A Tribute Portfolio by Marriott

1047 Fifth Avenue

San Diego, CA 92101

12:00 PM	Registration and Lunch	
	Introductory Remarks and Program Overview	
1:30 PM	Welcome, Forum Updates, Program Overview, and Acknowledgments	<i>Mitchell Leus, Forum for Collaborative Research</i>
1:40 PM	Steering Committee Co-Chair Welcoming Remarks	<i>Veronica Miller, Forum for Collaborative Research</i>
		<i>Terry Wright, GSK</i>
	Session I: Towards Standardizing HBV Nomenclature: Implications for Drug Development & Beyond	
	Moderators: <i>Veronica Miller, Forum for Collaborative Research & Carey Hwang, Vir Biotechnology</i>	
1:45 PM	Current issues with HBV nomenclature and a call for alignment	<i>Su Wang, Center for Asian Health, Cooperman Barnabas Medical Center, Global Health Advisor, Hepatitis B Foundation</i>
1:55 PM	Evolving understanding on HBV infection and reframing stages	<i>Mark Sulkowski, Johns Hopkins University</i>
2:05 PM	Learnings from Alaska Cohort	<i>Brian McMahon, Alaska Native Tribal Health Consortium</i>
2:10 PM	Panel Perspectives	<i>Eric Donaldson, FDA Center for Drug Evaluation and Research *</i>
		<i>Poonam Mishra, FDA Center for Drug Evaluation and Research</i>
		<i>Wendy Spearman, University of Cape Town</i>
2:25 PM	How Do We Move Forward	<i>Markus Cornberg, Hannover Medical School *</i>
		<i>Marc Ghany, NIH/NIDDK</i>
		<i>Seng Gee Lim, National University Hospital, Singapore</i>
2:35 PM	Open Discussion: What are areas we need consensus on, any low hanging fruit, what are next steps?	<i>All Meeting Participants</i>
	Session II: Novel Ways for Hepatocellular Carcinoma Surveillance in Patients with Chronic Hepatitis B	
	Moderators: <i>Bob Gish, Hepatitis B Foundation & Seng Gee Lim, National University Hospital, Singapore</i>	
3:10 PM	HCC Surveillance in HBV - Recognising and Stratifying Oncological Risk for Patients	<i>Kosh Agarwal, King's College Hospital NHS Foundation</i>
3:25 PM	Industry Rapid Fire Talks: Novel Tools for HCC Surveillance	<i>Elle Grevstad, Exact Sciences</i>
		<i>Shivani Mahajan, Helio Genomics</i>
		<i>George Rogge, FUJIFILM Healthcare Americas Corp.</i>
3:40 PM	Panel Discussion	<i>Chari Cohen, Hepatitis B Foundation</i>
		<i>Grace Dolman, GSK</i>
		<i>Mark Sonderup, University of Cape Town</i>
4:05 PM	Open Discussion	<i>All Meeting Participants</i>
4:20 PM	Break	

	Session III: Immune Checkpoint Inhibitors Working Group	
	Moderators: Sue Currie, Virion Therapeutics & Adam Gehring, Toronto Centre for Liver Disease	
4:50 PM	Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its Potential Use for Chronic Hepatitis B (CHB) Patients	<i>Agustina Crespi, Toronto Centre for Liver Disease</i> <i>Mitchell Leus, Forum for Collaborative Research</i>
5:00 PM	Discussion on clinical insights and benefit-risk	<i>Ed Gane, University of Auckland</i>
5:20 PM	Open Discussion	<i>All Meeting Participants</i>
	Session IV: HDV Assay Development Working Group	
	Moderators: Veronica Miller, Forum for Collaborative Research & Terry Wright, GSK	
5:45 PM	Panel Discussion: What is a standard case definition of HDV infection?	<i>Tom Battersby, Gilead Sciences</i> <i>Kat Whitaker, FDA Center for Devices and Radiological Health *</i>
6:05 PM	Open Discussion	<i>All Meeting Participants</i>
6:25 PM	Meeting Wrap Up and Adjourn	
6:30 PM	HBV, Liver, and PSC Forums Networking Reception	

* Indicates remote participation